CSL (ASX:CSL) has outlined a restructuring plan that includes separating its Seqirus influenza vaccine business into a standalone entity. The company is also planning workforce reductions and the ...

Is there more pain in store for CSL shareholders? The post Where to from here for CSL shares according to Macquarie appeared first on The Motley Fool Australia.

Haemonetics (NYSE:HAE) reported fiscal fourth-quarter revenue of $346 million, up 5% on a reported basis and 9% organically excluding CSL, as strength in its Plasma and Blood Management Technologies ...

This Nürburgring Nordschleife track compilation highlights the best moments from Brünnchen 2, known as YouTube Corner. With ...

The markets are a volatile terrain; however, the bulls are trying their best to fight back. The Nifty is up over 70 points, jumping to the 23,750 mark. The Sensex is up over 250 points, rising to ...

CSL Ltd. plunged the most on record after the Australian biotechnology company cut its full-year outlook and flagged about $5 billion in additional impairments, warning a turnaround will take longer ...

Approximated TTM Subscription Revenue Contribution for ≥$30K ARR Customers Grew 21% year-over-year Announced Share Repurchase Program with Initial Authorization of $50 Million CHICAGO, May 07, 2026 ...

Here's what brokers are recommending as buys this week. The post Top brokers name 3 ASX shares to buy now appeared first on The Motley Fool Australia.

Detailed price information for Haemonetics Corp (HAE-N) from The Globe and Mail including charting and trades.

Explore Bloomberg’s 2026 Dividend Focus: 16 safer high-yield stocks with strong FCF, top picks, and 2027 upside forecasts—see ...

Children’s Community Physicians Association (CCPA) and CCPA Purchasing Partners, LLC (CCPAPP) successfully concluded its 2026 Annual Meeting: Time for a Check-Up, bringing together over 100 providers ...

Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a messenger RNA medicines company focused on ...